GlassScriptPhysician profile
Crystal Elisabeth Mitchell
NPI 1841377512
$2,049.21
in general payments reported to CMS, 2019-2025
22 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $380 · 2023: $371 · 2024: $478 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.00 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $361.67 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $331.55 | 2021-2025 | |
| Lilly USA, LLC | $291.92 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $172.94 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $138.58 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Xeris Pharmaceuticals, INC. | $79.52 | 2023-2024 | Gvoke Hypopen |
| Averitas Pharma INC. | $72.11 | 2024-2025 | Qutenza |
| Pfizer INC. | $67.07 | 2022-2024 | |
| Abbott Laboratories | $61.89 | 2022-2025 | Freestyle Libre 2 |
| Amgen INC. | $60.92 | 2021-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $57.63 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.16 | 2022-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $36.47 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.67 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2023 | Rexulti |
| Amarin Pharma, INC. | $17.73 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.34 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2024 | Sotyktu |
| Horizon Therapeutics Plc | $13.98 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.